- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02667678
5 Years Follow-up Evaluation of Deterioration Kidney Biomarkers of HIV Patients (HIVOL2)
5 Years Follow-up Evaluation of Deterioration Kidney Biomarkers of HIV Patients : HIVOL 2 Study.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The aim of this study is to compare the biomarkers levels as IL-18, KIM-1 and Cystatin C for patients infected by HIV with failure in renal function at year 5. The main criterion will be a degradation of the glomerular filtration throughput measured. It will be compared to clinical scores of degradation risks of renal function for patients infected with HIV.
From 2011 to 2013, researchers realized a study called HIVOL, on the diagnostic performance of GFR (Glomerular Filtration Rate) estimators in patients infected with HIV. It lead to a publication in AIDS, retaken in the rational of recommendations of Infectious Diseases Society of America for the Chronic Renal Diseases support for patients infected with HIV.
235 patients were involved, for everyone researchers have a GFR measure (by Iohexol plasmatic clearance) and urinary and plasma samples.
Studietype
Registrering (Faktiske)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
-
Saint-etienne, Frankrike, 42100
- Chu Saint Etienne
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patient affiliated or entitled to a social security scheme
- Patient HIV infected
- Patient included in the HIVOL cohort with a GFR measure available
- Patients who have given their consent in writing
Exclusion Criteria:
- Pregnant or lactating women
- Patients treated with metformin
- Patients with a known allergy, regardless the type of allergy
- Patients with a history of thyroid dysfunction
- Any biological anomaly in the selection, which in the opinion of the investigator, may indicate a contraindication to the patient's participation in this study
- Degradation recent (not older than three months) of renal function defined as the degradation of more than 25 % GFR.
- Estimated GFR of less than 15 mL / min / 1.73m2
- History of major immediate or delayed skin reaction known to the injection of iodinated contrast medium (OMNIPAQUE®)
- Manifest thyrotoxicosis
- Hypersensitivity to the active substance or to any of the excipients (OMNIPAQUE®)
- Patient who expressed his refusal to participate in the study
- Patient justice under protection
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Cohort HIVOL, patients infected by HIV
Patients enrolled in HIVOL cohort (study performed between 2011 and 2013) will be contacted to participate to HIVOL-2.
The intervention will be blood and urinary samples, with the use of iohexol (Omnipaque®) to have an idea on renal plasmatic clearance.
|
Researchers will take blood and urinary samples from the patients of the HIVOL cohort, to look at the renal clearance.
The aim of this study is to check the renal function of the patients infected by HIV.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Stage of chronic kidney disease (according to the Glomerular Filtration Rate)
Tidsramme: Day 1
|
The aim of this study is to compare the level of biological biomarkers as microalbuminuria, proteinuria, KIM-1, IL-18, and Cystatin C with the level of this markers 5 years ago, for the HIVOL study performed between 2011 and 2013.
These levels will allow the researchers to have an idea concerning the renal function of the patients followed.
|
Day 1
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: GAGNEUX-BRUNON Amandine, MD, Chu Saint Etienne
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 1508032
- 2015-001455-68 (EudraCT-nummer)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRekrutteringHIV | HIV-testing | HIV-kobling til omsorg | HIV-behandlingForente stater
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationFullførtPartner HIV-testing | Par HIV-rådgivning | Parkommunikasjon | HIV-forekomstKamerun, Den dominikanske republikk, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement og andre samarbeidspartnereUkjentHIV | HIV-uinfiserte barn | Barn utsatt for HIVKamerun
-
University of MinnesotaTilbaketrukketHIV-infeksjoner | HIV/AIDS | Hiv | AIDS | Aids/Hiv problem | AIDS og infeksjonerForente stater
-
CDC FoundationGilead SciencesUkjentHIV-preeksponeringsprofylakse | HIV kjemoprofylakseForente stater
-
Hospital Clinic of BarcelonaFullførtIntegrasehemmere, HIV; HIV PROTEASE HEMMINGSpania
-
Erasmus Medical CenterHar ikke rekruttert ennåHIV-infeksjoner | Hiv | HIV-1-infeksjon | HIV I infeksjonNederland
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London og andre samarbeidspartnereRekrutteringHIV | HIV-testing | Kobling til omsorgSør-Afrika
-
University of WashingtonNational Institute of Mental Health (NIMH)RekrutteringHIV-forebygging | HIV-preeksponeringsprofylakse | GjennomføringKenya
-
University of Maryland, BaltimoreTilbaketrukketHiv | Nyretransplantasjon | HIV-reservoar | CCR5Forente stater